



RECEIVED

FEB 01 2001

TECH CENTER 1600/2800

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re prior application of: Ram PRATAP, et al.

Application No.: 09/316,313

Group No. 1625

Filed: May 21, 1999

Examiner: E. HUANG

For: METHOD FOR THE TREATMENT OF MALARIA BY THE USE OF PRIMAQUINE
DERIVATIVE N¹-(3-ETHYLIDINOTETRAHYDR-2-ONE)-N⁴-(6-METHOXY-8-QUINOLINYL)-1,4-
POENTANEDIAMINE AS GAMETOCYTOCIDAL AGENT

Attorney Docket: U 013003-3

Commissioner of Patents and Trademarks
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Prior to an examination of this Continued Prosecution Application on the merits
please amend the application as follows:

CERTIFICATION UNDER 37 C.F.R. 1.10**(Express Mail label number is **mandatory**.)**(Express Mail certification is optional.)*

I hereby certify that this correspondence and the documents referred to as attached therein are being deposited with the United States Postal Service on this date JANUARY 26, 2001, in an envelope as "Express Mail Post Office to Addressee," Mailing Label Number EL728210754US, addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

GERALDINE MARTI*(type or print name of person mailing paper)*Signature of person mailing paper**WARNING:**

Certificate of mailing (first class) or facsimile transmission procedures of 37 C.F.R. 1.8 cannot be used to obtain a date of mailing or transmission for this correspondence.

***WARNING:**

*Each paper or fee filed by "Express Mail" **must** have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. 1.10(b).
"Since the filing of correspondence under § 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will **not** be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.*

EL728210754US